Tagged as: biosimilar

Adalvo Expands Biosimilars Portfolio Through Acquisition of Romiplostim Biosimilar Program from Enzene

Adalvo announced on October 27, 2026 that it acquired Enzene’s romiplostim biosimilar program. The program references Amgen’s NPLATE®, which is indicated to treat adult and chronic pediatric immune thrombocytopenia (ITP).  Romiplostim, a Fc-peptide fusion protein (peptibody), is a thrombopoietin receptor agonist (TPO-RA). The acquisition combines Adalvo’s global development, regulatory and…

Read More

Celltrion Targets European Secukinumab Market with EMA Filing for CT-P55

Celltrion has submitted a Marketing Authorization Application to the European Medicines Agency (“EMA”) for CT-P55, its biosimilar to Novartis’ COSENTYX® (secukinumab). The application covers all indications held by COSENTYX® in Europe, including plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, and hidradenitis suppurativa. According to Celltrion, CT-P55 has demonstrated…

Read More

Celltrion Announces AVTOZMA (tocilizumab-anoh) Now Available in U.S.

On March 16, 2026, Celltrion, Inc. announced the U.S. commercial launch of AVTOZMA® (tocilizumab-anoh) SC, a subcutaneous formulation of its tocilizumab biosimilar referencing Roche’s ACTEMRA. Celltrion had previously launched its intravenous AVTOZMA® in October 2025. With this new launch, AVTOZMA® becomes one of the first tocilizumab biosimilars to have both…

Read More

Amgen Launches Its Aflibercept Biosimilar In the U.S.

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar, Amgen announced on its Q3 earnings call last week that it has launched its aflibercept biosimilar, PAVBLU.  On the call, Murdo Gordon, Amgen’s Executive Vice President of…

Read More

Update: Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Case Now Complete

We previously reported on the opening post-trial briefs in Regeneron’s BPCIA case against Mylan and Biocon (who was added as a defendant after the original defendant, Mylan, transferred its rights to the aflibercept biosimilar to Biocon). Now, post-trial briefing is complete. The parties submitted their responsive briefs on July 24,…

Read More